![]() |
市場調查報告書
商品編碼
2169826
寵物骨關節炎治療市場預測至2034年-按療法、藥物類別、寵物種類、通路和地區分類的全球分析Pet Osteoarthritis Treatment Market Forecasts to 2034 - Global Analysis By Treatment Type, Drug Class, Pet Type, Distribution Channel, and By Geography |
||||||
根據 Stratistics MRC 的數據,預計到 2026 年,全球寵物骨關節炎治療市場規模將達到 33 億美元,並在預測期內以 8% 的複合年成長率成長,到 2034 年將達到 61 億美元。
寵物骨關節炎的治療包括藥物、生物製藥、營養療法和復健等乾預措施,旨在控制伴侶動物的關節疼痛、發炎、活動受限和功能衰退。該市場涵蓋藥物、生物製藥和再生醫學、營養補充劑和關節補充劑,以及復健和物理治療。治療方案包括非類固醇消炎劑(NSAIDs)、止痛藥、抗神經生長因子療法和其他疼痛管理藥物,主要透過獸醫院和診所、寵物藥局和線上藥局供應給犬貓。寵物壽命的延長、人們對動物疼痛管理意識的提高以及獸醫治療技術的進步正在推動市場發展。
老年伴侶動物骨關節炎盛行率增加
伴侶動物壽命的延長是寵物骨關節炎治療市場的主要動力。骨關節炎是一種慢性退化性關節疾病,可導致持續疼痛、僵硬、活動受限以及日常生活困難。隨著犬貓壽命的延長,對獸醫診斷和長期疼痛管理的需求日益成長。寵物飼主對運動功能變化和老齡化相關關節疾病的認知不斷提高,促使他們更早帶寵物就醫。藥物治療的進步,包括標靶生物製藥和成熟的抗發炎藥物,正在拓展可用的治療方案。此外,伴侶動物醫療保健支出的增加也推動了對處方藥、關節補充劑和復健支持服務的需求。
高昂的治療費用和長期用藥的局限性
寵物骨關節炎的治療費用可能成為治療的阻礙,尤其當動物需要長期服藥、定期獸醫諮詢、診斷測試和復健治療時。生物製藥和新型標靶治療可能比傳統藥物更昂貴,這可能會限制價格敏感飼主的選擇。長期藥物治療也需要適當的獸醫監督,因為適應症、禁忌症和副作用因動物而異。非類固醇消炎劑(NSAIDs)可能需要監測胃腸道、腎臟和肝臟的健康狀況,其他治療方法也各有其安全性的考量。此外,如果初期症狀輕微或難以與正常的老齡化相關變化區分,飼主可能會延誤治療,導致後續治療更加複雜。
生物療法和骨關節炎多方面治療的進展
標靶動物用藥品的進步和多樣化的治療方法為市場參與企業創造了新的機會。抗NGF單株抗體療法為治療骨關節炎相關疼痛提供了一種新的機制,而藥物治療、營養補充劑、體重管理和物理治療則有助於制定個人化的護理方案。長效療法的引入還可以減少治療頻率,提高合格的患者的就醫便利性。此外,包括細胞療法和其他生物干預在內的再生醫學研究正在擴大潛在的治療選擇範圍。增加對獸醫臨床研究、診斷能力和專業教育的投入,將進一步促進整個伴侶動物醫療保健市場的創新和應用。
監管審查和治療方案之間的競爭
寵物骨關節炎治療市場面臨許多挑戰,例如監管要求、產品安全監測以及藥物和非藥物干預措施之間的競爭。動物用藥品必須證明其對目標適應症具有適當的安全性、有效性和質量,上市後監測結果可能導致標籤更新和處方實踐的改變。現有的非類固醇消炎劑(NSAIDs)與新型標靶治療、補充劑、復健服務和其他輔助療法競爭。不同動物對治療反應的差異也會影響獸醫和飼主的選擇。此外,雖然產品開發和臨床評估需要大量投資,但專利保護、商業化成本和市場准入要求也會影響競爭地位。製造商必須透過提供透明的安全資訊和持續產生臨床證據來維護消費者的信任。
新冠疫情透過診所營運的臨時限制、預約安排的調整、供應鏈中斷以及家庭支出的變化,對醫療保健產業產生了影響。一些常規獸醫預約和擇期檢查被推遲,這可能導致骨關節炎等慢性疾病的診斷和治療延誤。另一方面,居家時間的增加也讓一些飼主更重視寵物的健康和活動能力。獸醫院擴大採用數位溝通和預約管理工具,而在線購買某些寵物保健產品也變得更加重要。疫情過後,人們對預防性獸醫護理、寵物壽命和生活品質的關注依然存在,這支撐了對慢性疼痛管理、處方療法和輔助護理服務的需求。
在預測期內,醫藥領域預計將佔據最大的市場佔有率。
預計在預測期內,藥品領域將佔據最大的市場佔有率,這主要得益於處方藥在伴侶動物骨關節炎疼痛和發炎管理方面的廣泛應用。非類固醇消炎劑(NSAIDs) 和其他鎮痛藥仍然是犬貓治療相關疾病的重要選擇,獸醫專業人員會根據動物的病情、病歷和治療反應來選擇治療方案。成熟品牌和新型標靶治療的供應支撐了獸醫醫院和診所對藥品的需求。此外,慢性疾病的治療通常需要持續的治療和後續觀察,這也進一步推動了動物用藥品需求的持續成長。疼痛管理療法的不斷創新也進一步鞏固了藥品治療領域。
預計在預測期內,生物製藥和再生醫學領域將實現強勁成長。
隨著獸醫學在慢性關節疼痛標靶治療取得進展,生技藥品和再生醫學領域預計將實現強勁成長。抗NGF單株抗體療法透過不同於傳統非類固醇抗發炎藥物的作用機制,為犬貓骨關節炎的治療提供了更多選擇。長效生物製藥有望透過減少給藥頻率來提高治療便利性,而持續進行的再生醫學研究也激發了人們對旨在支持關節功能和組織健康的治療方法的興趣。人們對慢性疼痛管理的日益重視、對個人化治療需求的成長以及對獸醫治療領域的持續投入,都為該領域的發展提供了支持。
預計在預測期內,抗神經生長因子療法領域將實現強勁成長。
隨著標靶生物療法在獸醫學領域日益普及,用於治療骨關節炎相關疼痛,「抗神經生長因子(抗NGF)療法」細分市場預計將實現強勁成長。這些療法作用於神經生長因子(一種參與疼痛訊號傳導的蛋白質),為合格的伴侶動物提供了一種替代傳統抗發炎藥物的選擇。諸如犬用“Librela”和貓用“Solensia”等產品已在主要獸醫市場確立了抗NGF治療方案。隨著更多長效療法的推出,包括旨在提供更長時間鎮痛的新產品,治療選擇範圍正在擴大。獸醫對標靶治療的理解不斷加深以及對慢性疼痛管理日益成長的關注,預計將推動該細分市場的擴張。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其完善的獸醫基礎設施、龐大的伴侶動物醫療保健支出以及處方藥的廣泛供應。美國是動物用藥品動物用藥品、專業的生物製藥診所和完善的產品分銷網路。已獲監管部門批准的骨關節炎治療藥物的商業化,有助於提高寵物獲得治療的機會。此外,人們對老年寵物護理、定期獸醫檢查和慢性病管理的日益關注,也推動了對藥物治療、關節補充劑和復健服務的需求。這些因素鞏固了北美在寵物骨關節炎治療市場的領先地位。
預計亞太地區在預測期內將實現最高的複合年成長率,這主要得益於寵物飼養量的增加、獸醫服務網路的擴張、可支配收入的成長以及人們對動物健康意識的提高。都市化和家庭生活方式的改變正在推動獸醫諮詢、處方藥和預防性醫療保健方面的支出成長。在中國、日本、澳洲、韓國和印度,寵物專業醫療保健服務的普及為製藥企業和獸醫服務提供者創造了商機。在線獸藥的日益普及以及專業人士對慢性關節疾病認知的提高也促進了市場發展。預計這些趨勢將加速全部區域寵物骨關節炎治療的普及。
According to Stratistics MRC, the Global Pet Osteoarthritis Treatment Market is accounted for $3.3 billion in 2026 and is expected to reach $6.1 billion by 2034 growing at a CAGR of 8% during the forecast period. Pet osteoarthritis treatment encompasses pharmaceutical, biological, nutritional, and rehabilitative interventions designed to manage joint pain, inflammation, mobility limitations, and functional decline in companion animals. The market includes pharmaceuticals, biologics and regenerative therapies, nutraceuticals and joint supplements, and rehabilitation and physical therapy. Treatment options include nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, anti-nerve growth factor therapies, and other pain-management drugs, primarily serving dogs and cats through veterinary hospitals and clinics, veterinary pharmacies, and online pharmacies. Increasing pet longevity, growing awareness of animal pain management, and advances in veterinary therapeutics are supporting market development.
Increasing prevalence of osteoarthritis in aging companion animals
The growing population of aging companion animals is a major driver of the pet osteoarthritis treatment market. Osteoarthritis is a chronic degenerative joint condition that can cause persistent pain, stiffness, reduced mobility, and difficulty performing everyday activities. As dogs and cats live longer, demand for veterinary assessment and long-term pain management is increasing. Greater awareness among pet owners of mobility changes and age-related joint disorders is encouraging earlier veterinary consultations. Advances in pharmaceutical treatments, including targeted biological therapies and established anti-inflammatory medications, are expanding the available treatment options. Additionally, increasing expenditure on companion animal healthcare is supporting demand for prescription medications, joint supplements, and supportive rehabilitation services.
High treatment costs and limitations associated with long-term medication use
The cost of managing pet osteoarthritis can constrain treatment uptake, particularly when animals require ongoing medication, veterinary consultations, diagnostic examinations, and rehabilitation. Biological therapies and newer targeted treatments may involve higher costs than conventional medications, potentially limiting access among price-sensitive pet owners. Long-term pharmaceutical management also requires appropriate veterinary supervision because treatment suitability, contraindications, and adverse effects vary across animals. NSAIDs may require monitoring of gastrointestinal, kidney, and liver health, while other therapies have their own safety considerations. In addition, owners may delay treatment when early symptoms are subtle or difficult to distinguish from normal age-related changes, potentially increasing the complexity of subsequent care.
Advancements in biological therapies and multimodal osteoarthritis management
Advances in targeted veterinary medicines and multimodal treatment approaches are creating opportunities for market participants. Anti-NGF monoclonal antibody therapies provide an alternative mechanism for managing osteoarthritis-associated pain, while pharmaceutical treatments, nutritional supplements, weight management, and physical rehabilitation can contribute to individualized care plans. The introduction of longer-acting therapies may also reduce the frequency of treatment administration and improve convenience for eligible patients. Additionally, research into regenerative medicine, including cell-based approaches and other biological interventions, is expanding the range of potential treatment options. Growing investment in veterinary clinical research, diagnostic capabilities, and professional education can further support innovation and adoption across companion animal healthcare markets.
Regulatory scrutiny and competition among treatment alternatives
The pet osteoarthritis treatment market faces challenges from regulatory requirements, product safety monitoring, and competition among pharmaceutical and non-pharmaceutical interventions. Veterinary medicines must demonstrate appropriate safety, efficacy, and quality for their intended indications, while post-marketing surveillance can lead to labeling updates and changes in prescribing practices. Established NSAIDs compete with newer targeted therapies, supplements, rehabilitation services, and other supportive approaches. Differences in treatment response among individual animals can also influence veterinary and owner preferences. Furthermore, product development and clinical evaluation require substantial investment, while patent protection, commercialization costs, and market access requirements can affect competitive positioning. Manufacturers must maintain confidence through transparent safety communication and continued clinical evidence generation.
The COVID-19 pandemic affected veterinary healthcare through temporary clinic restrictions, changes in appointment availability, supply chain disruptions, and shifts in household spending. Some routine veterinary consultations and elective assessments were postponed, potentially delaying the diagnosis and management of chronic conditions such as osteoarthritis. At the same time, increased time spent at home heightened some pet owners' awareness of companion animal health and mobility. Veterinary practices increasingly adopted digital communication and appointment management tools, while online purchasing gained importance for certain pet healthcare products. Following the pandemic, the continued focus on preventive veterinary care, pet longevity, and quality of life has supported demand for chronic pain management, prescription therapies, and supportive treatment services.
The Pharmaceuticals segment is expected to be the largest during the forecast period
The Pharmaceuticals segment is expected to account for the largest market share during the forecast period, supported by the established use of prescription medications to manage osteoarthritis-associated pain and inflammation in companion animals. NSAIDs and other analgesics remain important treatment options for eligible dogs and cats, with veterinary professionals selecting therapies according to the animal's condition, medical history, and treatment response. The availability of established brands and newer targeted medicines supports pharmaceutical demand across veterinary hospitals and clinics. In addition, chronic disease management often requires ongoing treatment and follow-up consultations, contributing to recurring demand for veterinary medications. Continued innovation in pain-management therapies is further strengthening the pharmaceutical treatment landscape.
The Biologics and Regenerative Therapies segment is expected to witness strong growth during the forecast period
The Biologics and Regenerative Therapies segment is expected to experience strong growth as veterinary medicine advances toward targeted approaches for managing chronic joint pain. Anti-NGF monoclonal antibody therapies have expanded treatment options for canine and feline osteoarthritis, offering a mechanism distinct from conventional NSAIDs. Longer-acting biological products may improve convenience by reducing administration frequency, while continued research into regenerative medicine is generating interest in approaches intended to support joint function and tissue health. Growing awareness of chronic pain management, increasing demand for individualized treatment, and continued investment in veterinary therapeutics are supporting segment development.
The Anti-Nerve Growth Factor Therapies segment is expected to witness strong growth during the forecast period
The Anti-Nerve Growth Factor Therapies segment is expected to record strong growth as veterinary medicine increasingly adopts targeted biological treatments for osteoarthritis-associated pain. These therapies act on nerve growth factor, a protein involved in pain signaling, and provide an alternative to conventional anti-inflammatory medication for eligible companion animals. Products such as Librela for dogs and Solensia for cats have established anti-NGF treatment options in major veterinary markets. The introduction of additional long-acting therapies, including newer products designed to provide pain relief for longer intervals, is broadening the treatment landscape. Greater veterinary familiarity with targeted therapeutics and increasing attention to chronic pain management are expected to support segment expansion.
During the forecast period, North America is expected to hold the largest market share, supported by established veterinary healthcare infrastructure, substantial companion animal healthcare expenditure, and broad availability of prescription treatments. The United States represents a major market for veterinary pharmaceuticals and biological therapies, supported by established animal health companies, specialist veterinary practices, and product distribution networks. Regulatory approvals and commercial availability of established osteoarthritis medicines contribute to treatment accessibility. Furthermore, increasing attention to senior pet care, routine veterinary examinations, and chronic disease management supports demand for pharmaceutical interventions, joint supplements, and rehabilitation services. These factors reinforce North America's leading position in the pet osteoarthritis treatment market.
The Asia Pacific region is expected to witness the highest CAGR during the forecast period, driven by increasing companion animal ownership, expanding veterinary service networks, rising disposable incomes, and growing awareness of animal health. Urbanization and changing household lifestyles are supporting expenditure on veterinary consultations, prescription medicines, and preventive healthcare. China, Japan, Australia, South Korea, and India offer opportunities for pharmaceutical manufacturers and veterinary service providers as access to specialized pet healthcare expands. Increasing availability of online veterinary pharmacies and growing professional awareness of chronic joint disorders are also supporting market development. These trends are expected to accelerate adoption of pet osteoarthritis treatments across the region.
Key players in the market
Some of the key players in the Global Pet Osteoarthritis Treatment Market include Zoetis Inc., Boehringer Ingelheim, Elanco Animal Health Incorporated, Dechra Pharmaceuticals PLC, Virbac, Vetoquinol S.A., Kindred Biosciences, American Regent Animal Health, Nutramax Laboratories Veterinary Sciences, Inc., and Assisi Animal Health.
In October 2026, Boehringer Ingelheim announced the availability of its new Quarterable Snap-Tab design for PREVICOX (firocoxib) chewable tablets in the United States following FDA approval. The updated design enables tablets to be divided into quarters, providing more flexible dosing options based on dogs' body weight and improving convenience for veterinary professionals and pet owners.
In September 2026, Zoetis launched Lenivia (izenivetmab injection) in Great Britain. The long-acting monoclonal antibody therapy is designed to alleviate osteoarthritis-associated pain in dogs for up to three months following a single injection, expanding treatment options for canine chronic pain management.
In July 2026, Zoetis launched Lenivia in Canada and European Union member states. The commercial expansion increased the availability of its long-acting canine osteoarthritis treatment across additional veterinary markets and strengthened the company's targeted pain-management portfolio.
In July 2026, Zoetis launched Portela (relfovetmab) in Canada and the European Union. The long-acting anti-NGF monoclonal antibody therapy for cats is designed to provide osteoarthritis-associated pain relief for up to three months following a single subcutaneous injection, expanding biological treatment options for feline osteoarthritis.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.